0Y2 Stock Chart & Stats
€1.59
-€0.25(-4.63%)
At close: 4:00 PM EST
€1.59
-€0.25(-4.63%)
Day’s Range― - ―
52-Week Range€1.21 - €2.80
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€37.74M
Enterprise Value€10.19
Total Cash (Recent Filing)€21.36M
Total Debt (Recent Filing)€1.51M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Aug 05, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.69
Shares Outstanding26,585,258
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.76
Price to Sales (P/S)829.46
P/FCF Ratio-1.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€7.03Price Target Upside342.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.66
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
CORDStrom Regulatory & Manufacturing ProgressConcrete regulatory steps (PIP submission, MAA preparation) plus started process-validation runs materially de-risk the CORDStrom pathway. These milestones strengthen the company’s ability to pursue conditional UK approval and parallel EMA/FDA filings, improving prospects for commercialization and long-term platform credibility.
Secured Long-term Cord-tissue Supply & LicenseA formal long-term material transfer and exclusive license with Anthony Nolan secures critical raw material for CORDStrom, enhancing manufacturing reliability and regulatory traceability. This supply certainty supports scalable, off-the-shelf production and reduces operational risk tied to input availability over commercialization.
XPro Fast Track & Supportive Phase 2 MRI DataFast Track designation plus imaging-confirmed target engagement for XPro materially improve development efficiency and regulator engagement. These factors support a precision-medicine registrational strategy, potentially shortening review timelines and enhancing partner interest for a differentiated Alzheimer’s program.
Bears Say
Pre-commercial With Zero TTM RevenueNo product revenue and persistent, sizable net losses mean the business cannot self-fund operations. Over multi-quarter horizons this necessitates external financing, increases dilution risk, and constrains reinvestment capacity, limiting strategic optionality and heightening execution risk for core programs.
Limited Cash RunwayA roughly one-year runway creates a high probability of near-term fundraising or dilutive transactions. That pressure can force suboptimal financing timing, distract management, and constrain spending on trials, manufacturing scale-up, and commercialization prep—raising the chance of slowed program execution.
Material Reduction In R&D SpendA large, sustained cut in R&D spending reduces near-term cash burn but risks slowing data generation, delaying pivotal trials and regulatory submissions, and weakening competitive differentiation. For a clinical-stage biotech, reduced investment can lengthen timelines and lower probability of achieving key milestones.
Inmune Bio News
0Y2 FAQ
What was Inmune Bio’s price range in the past 12 months?
Inmune Bio lowest stock price was €1.21 and its highest was €2.80 in the past 12 months.
What is Inmune Bio’s market cap?
Inmune Bio’s market cap is €37.74M.
When is Inmune Bio’s upcoming earnings report date?
Inmune Bio’s upcoming earnings report date is Aug 05, 2026 which is in 9 days.
How were Inmune Bio’s earnings last quarter?
Inmune Bio released its earnings results on May 07, 2026. The company reported -€0.175 earnings per share for the quarter, beating the consensus estimate of -€0.215 by €0.039.
Is Inmune Bio overvalued?
According to Wall Street analysts Inmune Bio’s price is currently Undervalued.
Does Inmune Bio pay dividends?
Inmune Bio does not currently pay dividends.
What is Inmune Bio’s EPS estimate?
Inmune Bio’s EPS estimate is -0.18.
How many shares outstanding does Inmune Bio have?
Inmune Bio has 26,585,258 shares outstanding.
What happened to Inmune Bio’s price movement after its last earnings report?
Inmune Bio reported an EPS of -€0.175 in its last earnings report, beating expectations of -€0.215. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Inmune Bio?
Currently, no hedge funds are holding shares in DE:0Y2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inmune Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€7.03 (342.28% Upside)
€7.03 (342.28% Upside)
Blogger Sentiment
Bullish
DE:0Y2 Sentiment 70%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
-41.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-31.70%
Trailing 12-Months
Company Description
Inmune Bio
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
0Y2 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful, tangible progress toward a key inflection point: CORDStrom advanced through regulatory planning (PIP approval), manufacturing validation runs began, and a long-term supply agreement was secured — all supportive milestones. XPro imaging work and partnership exploration were also positive. Offsetting these positives are schedule/regulatory timing shifts, a materially limited cash runway (funding through Q1 2027), and a large year-over-year reduction in R&D spend that could indicate slower near-term investment. Overall the call shows constructive execution on regulatory and manufacturing fronts but meaningful financing and execution risks remain.View all DE:0Y2 earnings summaries0Y2 Stock 12 Month Forecast
Average Price Target
€7.03
▲(342.28% Upside)
Technical Analysis
Veru
―
Karyopharm Therapeutics
―
Cue Biopharma
―
Celularity
―
Jupiter Neurosciences, Inc.
―